Maven Securities LTD Invests $3.55 Million in Spyre Therapeutics, Inc. $SYRE

Key Points

• Maven Securities acquired 40,000 shares of Spyre Therapeutics worth approximately $3.55 million in the second quarter. Institutional investors collectively own 80.39% of the company.
• Wall Street’s consensus rating is “Moderate Buy”, with an average price target of $109.69, although analyst views range from “Strong Buy” to “Sell.”
• Spyre shares opened at $90.79, while insiders sold 180,465 shares worth $16.64 million during the latest quarter. The company also reported a quarterly loss of $0.36 per share, beating estimates for a $0.76 loss.

Maven Securities LTD acquired a new stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 40,000 shares of the company's stock, valued at approximately $3,551,000.

A number of other institutional investors and hedge funds have also bought and sold shares of SYRE. Summit Securities Group LLC acquired a new position in Spyre Therapeutics during the 1st quarter valued at $28,000. GAMMA Investing LLC grew its position in Spyre Therapeutics by 26.8% in the 2nd quarter. GAMMA Investing LLC now owns 663 shares of the company's stock worth $59,000 after purchasing an additional 140 shares during the last quarter. KBC Group NV bought a new position in shares of Spyre Therapeutics during the 1st quarter worth about $69,000. Russell Investments Group Ltd. raised its position in shares of Spyre Therapeutics by 2,881.7% during the third quarter. Russell Investments Group Ltd. now owns 4,234 shares of the company's stock valued at $71,000 after buying an additional 4,092 shares during the last quarter. Finally, Persistent Asset Partners Ltd acquired a new position in shares of Spyre Therapeutics during the fourth quarter valued at about $74,000. Institutional investors own 80.39% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on SYRE shares. Deutsche Bank Aktiengesellschaft decreased their target price on Spyre Therapeutics from $135.00 to $127.00 and set a "buy" rating on the stock in a research report on Wednesday, August 26th. Wolfe Research downgraded Spyre Therapeutics from an "outperform" rating to a "peer perform" rating in a research report on Tuesday, July 28th. BTIG Research reissued a "buy" rating and set a $121.00 price objective on shares of Spyre Therapeutics in a report on Tuesday. Wall Street Zen cut Spyre Therapeutics from a "hold" rating to a "sell" rating in a research report on Sunday, August 16th. Finally, Mizuho upped their target price on Spyre Therapeutics from $84.00 to $120.00 and gave the company an "outperform" rating in a research note on Monday, July 13th. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $109.69.

Insider Buying and Selling

In other Spyre Therapeutics news, Director Jeffrey W. Albers sold 18,000 shares of Spyre Therapeutics stock in a transaction on Friday, August 7th. The stock was sold at an average price of $104.55, for a total transaction of $1,881,900.00. Following the completion of the transaction, the director directly owned 9,360 shares of the company's stock, valued at approximately $978,588. This trade represents a 65.79% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Cameron Turtle sold 15,000 shares of the company's stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $87.29, for a total transaction of $1,309,350.00. Following the completion of the sale, the chief executive officer directly owned 552,540 shares in the company, valued at approximately $48,231,216.60. The trade was a 2.64% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 180,465 shares of company stock worth $16,638,714 in the last quarter. Corporate insiders own 15.69% of the company's stock.

Spyre Therapeutics Stock Up 2.0%

Shares of SYRE opened at $90.79 on Wednesday. The stock has a market cap of $7.98 billion, a price-to-earnings ratio of -46.56 and a beta of 2.99. Spyre Therapeutics, Inc. has a 12 month low of $14.51 and a 12 month high of $110.18. The company has a 50-day moving average price of $98.07 and a two-hundred day moving average price of $75.65.

Spyre Therapeutics (NASDAQ:SYRE - Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.76) by $0.40. Equities research analysts expect that Spyre Therapeutics, Inc. will post -2.62 EPS for the current fiscal year.

About Spyre Therapeutics

Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for cancer. The company leverages proprietary protein engineering and biologics design platforms to create targeted molecules intended to enhance anti-tumor immune responses and inhibit tumor growth. Its preclinical pipeline comprises multiple candidate therapies for solid tumor and hematologic oncology indications.

Established by a team with deep expertise in protein design, immunology and translational research, Spyre Therapeutics collaborates with leading academic institutions and research organizations to accelerate its discovery efforts.

Want to see what other hedge funds are holding SYRE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.